Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women - Top-Institutions - MDSpire

Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women

  • By

  • Brunet, Louise

  • Busiah, Kanetee

  • Moser, Mireille

  • Papadakis, Georgios E.

  • May 21, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Endocrinology

  • #2

    Young Women’s Breast Cancer Study
    Young Women’s Breast Cancer Study

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Endocrinology

  • #3

    IEO Breast Cancer Cohort
    IEO Breast Cancer Cohort

    Milan, Italy

    Key Differentiators

    • Oncology
    • Endocrinology

  • #4

    Women’s College Hospital Research and Innovation Institute
    Women’s College Hospital Research and Innovation Institute

    Toronto, Ontario

    Key Differentiators

    • Women's Health
    • Endocrinology

Original Source(s)

Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women

  • by Brunet, Louise , Busiah, Kanetee , Moser, Mireille , Papadakis, Georgios E.

  • May 21, 2026

Related Content

Correction to: “Comments on Injectable Estradiol Use in Transgender and Gender-diverse Individuals in the United States”

  • January 7, 2026

Effects of gender-affirming hormone therapy from adolescence to adulthood on cardiovascular function: a cross-sectional study

Texas Emerges as Focus of New Trump Administration Actions to Limit Gender-Affirming Care